Efficacy and Safety of PF-00299804 (PF299), an Oral, Irreversible, Pan-human Epidermal Growth Factor Receptor (pan-HER) Tyrosine Kinase Inhibitor (TKI), as First-Line Treatment (tx) of Selected Patients (pts) with Advanced (adv) Non-Small Cell Lung Cancer (NSCLC)
Refereed conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者MOK Shu Kam Tony, SPIGEL R D, PARK K, SOCINSKI A M, TUNG Y S, KIM D, BORZILLO G, ZHANG H, OCONNELL P J, JANNE A P
會議名稱ASCO Annual Meeting 2010
會議國家/地區美國
會議論文集題名ASCO Annual Meeting 2010
詳細描述organized by American Society of Clinical Oncology,
出版年份2010
月份6
出版地United States of America
頁次7537
語言英式英語
關鍵詞PF299; pan-HER; NSCLC

上次更新時間 2018-18-01 於 16:47